Leaders in oncology share why the American Society of Clinical Oncology (ASCO) meeting remains a top global gathering for breakthroughs, networking, and lifelong learning. Oncology professionals ...

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced presentations on Axumin® (fluciclovine F ...

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify [email protected] if there are concerns ...

ASCO 2021 New Long-term Melanoma Data 'Clearly Favor' IPI/NIVO Dr Jeffrey Weber discusses long-term follow-up data presented at ASCO 2021. Medscape Oncology, August 03, 2021 Our Immunocompromised ...

ASCO 2021 New Long-term Melanoma Data 'Clearly Favor' IPI/NIVO Dr Jeffrey Weber discusses long-term follow-up data presented at ASCO 2021. Medscape Oncology, August 03, 2021 Physicians Behaving Badly: ...

Artificial intelligence (AI) models can generate scientific abstracts that are difficult to distinguish from the work of human authors. The use of AI in scientific writing and performance of AI ...

Median Duration of Response (DOR) Not Reached at 33.1 Months of Median Study Follow Up in Cohort 2 in C-144-01 Study Early Intervention with Lifileucel Following Progression on Anti-PD-1 Therapy May ...

Biosimilars offer increased patient choice and potential cost-savings, compared with originator biologics. We studied 3 years of prescribed biologics among US physician practices to determine the ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Today, Sarah Cannon announced it will present its latest cancer research insights at the American Society of Clinical Oncology’s (ASCO®) Annual Meeting being held ...

Emerson has announced the recipients of its 2021 ASCO™ Engineering Scholarship Program, continuing its long-standing commitment to rewarding and supporting students dedicated to innovating the future ...

– Efficacy benefits with recently approved combination regimen observed regardless of baseline International Metastatic Renal Cell Carcinoma Database Consortium risk status, organ site of metastases ...